Search: WFRF:(Hilpert Florian)
> (2017) >
Reducing Uncertaint...
-
Roncolato, Felicia T.University of Sydney, Australia; ANZGOG, Australia; Macarthur Cancer Therapy Centre, Australia
(author)
Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study
- Article/chapterEnglish2017
Publisher, publication year, extent ...
-
2017-06-08
-
WILEY,2017
-
printrdacarrier
Numbers
-
LIBRIS-ID:oai:DiVA.org:liu-141729
-
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-141729URI
-
https://doi.org/10.1634/theoncologist.2017-0047DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:136643975URI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
Funding Agencies|Australian National Health and Medical Research Council [GNT1063012]; Target Ovarian Cancer; Cancer Research U.K.; UCL Cancer Trials Centre [C444/A15953]; Department of Health
-
Background. Clinicians and patients often overestimate the benefits of chemotherapy, and overall survival (OS), in platinum resistant/refractory ovarian cancer (PRROC). This study sought to determine aspects of health-related quality of life and clinicopathological characteristics before starting chemotherapy that were associated with stopping chemotherapy early, shortened survival, and death within 30 days of chemotherapy. Materials and Methods. This study enrolled women with PRROC before starting palliative chemotherapy. Health-related quality of life was measured with EORTC QLQ-C30/QLQ-OV28. Chemotherapy stopped within 8 weeks of starting was defined as stopping early. Logistic regression was used to assess univariable and multivariable associations with stopping chemotherapy early and death within 30 days of chemotherapy; Cox proportional hazards regression was used to assess associations with progression-free and OS. Results. Low baseline global health status (GHS), role function (RF), physical function (PF), and high abdominal/gastrointestinal symptom (AGIS) were associated with stopping chemotherapy early (all pamp;lt;.007); low PF and RF remained significant after adjusting for clinicopathological factors (both pamp;lt;.0401). Most who stopped chemotherapy early had Eastern Cooperative Oncology Group Performance Score 0-1 at baseline (79%); PF, RF, and GHS remained independently significant predictors of stopping chemotherapy early in this subgroup. Death within 30 days of chemotherapy occurred in 14%. Low-GHS, RF, and PF remained significantly associated with death within 30 days of chemotherapy after adjusting for clinicopathological factors (all pamp;lt;.012). Conclusion. Women with low GHS, RF, or PF before starting chemotherapy were more likely to stop chemotherapy early, with short OS. Self-ratings of GHS, RF, and PF could improve patient-clinician communication regarding prognosis and help decision-making in women considering chemotherapy for PRROC.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Joly, FlorenceCentre Francois Baclesse, France
(author)
-
OConnell, RachelUniversity of Sydney, Australia
(author)
-
Lanceley, AnneUCL, England
(author)
-
Hilpert, FelixUKSH, Germany
(author)
-
Buizen, LukeUniversity of Sydney, Australia
(author)
-
Okamoto, AikouJikei University, Japan
(author)
-
Aotani, ErikoKitasato Academic Research Org, Japan
(author)
-
Pignata, SandroIRCCS, Italy
(author)
-
Donnellan, PaulGalway University Hospital, Ireland
(author)
-
Oza, AmitUniversity of Toronto, Canada
(author)
-
Åvall-Lundqvist, Elisabeth,1957-Karolinska Institutet,Linköpings universitet,Avdelningen för Kirurgi, Ortopedi och Onkologi,Medicinska fakulteten,Region Östergötland, Onkologiska kliniken US,Karolinska Institute, Sweden(Swepub:liu)eliav51
(author)
-
Berek, Jonathan S.Stanford Comprehens Cancer Institute, CA USA
(author)
-
Heitz, FlorianKEM, Germany; KEM, Germany
(author)
-
Feeney, AmandaCancer Research UK, England; UCL Cancer Trials Centre, England
(author)
-
Berton-Rigaud, DominiqueICO Centre Rene Gauducheau, France
(author)
-
Stockler, Martin R.University of Sydney, Australia; ANZGOG, Australia
(author)
-
King, MadeleineANZGOG, Australia; University of Sydney, Australia
(author)
-
Friedlander, MichaelANZGOG, Australia; Prince Wales Hospital, Australia
(author)
-
University of Sydney, Australia; ANZGOG, Australia; Macarthur Cancer Therapy Centre, AustraliaCentre Francois Baclesse, France
(creator_code:org_t)
Related titles
-
In:The Oncologist: WILEY22:9, s. 1117-11241083-71591549-490X
Internet link
Find in a library
To the university's database
- By the author/editor
-
Roncolato, Felic ...
-
Joly, Florence
-
OConnell, Rachel
-
Lanceley, Anne
-
Hilpert, Felix
-
Buizen, Luke
-
show more...
-
Okamoto, Aikou
-
Aotani, Eriko
-
Pignata, Sandro
-
Donnellan, Paul
-
Oza, Amit
-
Åvall-Lundqvist, ...
-
Berek, Jonathan ...
-
Heitz, Florian
-
Feeney, Amanda
-
Berton-Rigaud, D ...
-
Stockler, Martin ...
-
King, Madeleine
-
Friedlander, Mic ...
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cancer and Oncol ...
- Articles in the publication
-
The Oncologist
- By the university
-
Linköping University
-
Karolinska Institutet